Market Cap 258.10M
Revenue (ttm) 20,000.00
Net Income (ttm) -257.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,287,950.01%
Debt to Equity Ratio 0.00
Volume 3,019,000
Avg Vol 3,353,034
Day's Range N/A - N/A
Shares Out 218.73M
Stochastic %K 81%
Beta 0.60
Analysts Strong Sell
Price Target $8.35

Latest News on ALLO

Allogene Therapeutics: Disrupting CAR-T With A Scalable Model

Feb 24, 2025, 10:53 PM EST - 3 months ago

Allogene Therapeutics: Disrupting CAR-T With A Scalable Model


Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 12:34 AM EDT - 10 months ago

Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call Transcript


Showcasing Seeking Alpha's March 2024 New Analysts

Apr 4, 2024, 11:30 AM EDT - 1 year ago

Showcasing Seeking Alpha's March 2024 New Analysts

APD AXP CPS CPT DG DK EPR